340 related articles for article (PubMed ID: 36768443)
1. The Role of Arginine-Vasopressin in Stroke and the Potential Use of Arginine-Vasopressin Type 1 Receptor Antagonists in Stroke Therapy: A Narrative Review.
Chojnowski K; Opiełka M; Gozdalski J; Radziwon J; Dańczyszyn A; Aitken AV; Biancardi VC; Winklewski PJ
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768443
[TBL] [Abstract][Full Text] [Related]
2. Vasopressin and Vasopressin Antagonists in Heart Failure.
Vishram-Nielsen JK; Gustafsson F
Handb Exp Pharmacol; 2017; 243():307-328. PubMed ID: 28432473
[TBL] [Abstract][Full Text] [Related]
3. Effect of arginine vasopressin on the cortex edema in the ischemic stroke of Mongolian gerbils.
Zhao XY; Wu CF; Yang J; Gao Y; Sun FJ; Wang DX; Wang CH; Lin BC
Neuropeptides; 2015 Jun; 51():55-62. PubMed ID: 25843346
[TBL] [Abstract][Full Text] [Related]
4. Copeptin - a new diagnostic and prognostic biomarker in neurological and cardiovascular diseases.
Baranowska B; Kochanowski J
Neuro Endocrinol Lett; 2019 Dec; 40(5):207-214. PubMed ID: 32112544
[TBL] [Abstract][Full Text] [Related]
5. Vasopressin and Copeptin in health and disease.
Christ-Crain M
Rev Endocr Metab Disord; 2019 Sep; 20(3):283-294. PubMed ID: 31656992
[TBL] [Abstract][Full Text] [Related]
6. Copeptin: a biomarker of cardiovascular and renal function.
Morgenthaler NG
Congest Heart Fail; 2010 Jul; 16 Suppl 1():S37-44. PubMed ID: 20653710
[TBL] [Abstract][Full Text] [Related]
7. Vasopressin and Related Peptides; Potential Value in Diagnosis, Prognosis and Treatment of Clinical Disorders.
Szczepanska-Sadowska E; Zera T; Sosnowski P; Cudnoch-Jedrzejewska A; Puszko A; Misicka A
Curr Drug Metab; 2017; 18(4):306-345. PubMed ID: 28117000
[TBL] [Abstract][Full Text] [Related]
8. The role of copeptin in kidney disease.
Iglesias P; Silvestre RA; Fernández-Reyes MJ; Díez JJ
Endocrine; 2023 Mar; 79(3):420-429. PubMed ID: 36242751
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of Copeptin in Chronic Kidney Disease: From General Population to End-Stage Renal Disease.
Golembiewska E; Machowska A; Stenvinkel P; Lindholm B
Curr Protein Pept Sci; 2017; 18(12):1232-1243. PubMed ID: 28714397
[TBL] [Abstract][Full Text] [Related]
10. Association of copeptin, a surrogate marker of arginine vasopressin, with cerebral vasospasm and delayed ischemic neurologic deficit after aneurysmal subarachnoid hemorrhage.
Fernandez SJ; Barakat I; Ziogas J; Frugier T; Stylli SS; Laidlaw JD; Kaye AH; Adamides AA
J Neurosurg; 2018 May; 130(5):1446-1452. PubMed ID: 29726784
[TBL] [Abstract][Full Text] [Related]
11. Arginine-vasopressin V1 but not V2 receptor antagonism modulates infarct volume, brain water content, and aquaporin-4 expression following experimental stroke.
Liu X; Nakayama S; Amiry-Moghaddam M; Ottersen OP; Bhardwaj A
Neurocrit Care; 2010 Feb; 12(1):124-31. PubMed ID: 19806476
[TBL] [Abstract][Full Text] [Related]
12. Role of vasopressin V(1a) and V2 receptors for the development of secondary brain damage after traumatic brain injury in mice.
Trabold R; Krieg S; Schöller K; Plesnila N
J Neurotrauma; 2008 Dec; 25(12):1459-65. PubMed ID: 19118456
[TBL] [Abstract][Full Text] [Related]
13. Role of arginine vasopressin V1 and V2 receptors for brain damage after transient focal cerebral ischemia.
Vakili A; Kataoka H; Plesnila N
J Cereb Blood Flow Metab; 2005 Aug; 25(8):1012-9. PubMed ID: 15744246
[TBL] [Abstract][Full Text] [Related]
14. Copeptin in fluid disorders and stress.
Mu D; Ma C; Cheng J; Zou Y; Qiu L; Cheng X
Clin Chim Acta; 2022 Apr; 529():46-60. PubMed ID: 35143773
[TBL] [Abstract][Full Text] [Related]
15. Arginine vasopressin in mood disorders: A potential biomarker of disease pathology and a target for pharmacologic intervention.
Hu H; Zarate CA; Verbalis J
Psychiatry Clin Neurosci; 2024 Jun; ():. PubMed ID: 38923665
[TBL] [Abstract][Full Text] [Related]
16. Postoperative vasopressin and copeptin levels in noncardiac surgery patients: a prospective controlled trial.
Jochberger S; Zitt M; Luckner G; Mayr VD; Wenzel V; Ulmer H; Morgenthaler NG; Hasibeder WR; Dünser MW
Shock; 2009 Feb; 31(2):132-8. PubMed ID: 18650776
[TBL] [Abstract][Full Text] [Related]
17. Review novel insights into the diagnostic and prognostic function of copeptin in daily clinical practice.
Wu P; Wang L; Su X; Wang B; Cheng Y
Mol Biol Rep; 2023 Apr; 50(4):3755-3765. PubMed ID: 36662451
[TBL] [Abstract][Full Text] [Related]
18. Time-Dependent Effects of Arginine-Vasopressin V1 Receptor Inhibition on Secondary Brain Damage after Traumatic Brain Injury.
Krieg SM; Trabold R; Plesnila N
J Neurotrauma; 2017 Apr; 34(7):1329-1336. PubMed ID: 27762660
[TBL] [Abstract][Full Text] [Related]
19. Safety, tolerability, and pharmacokinetics of SR 49059, a V1a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers.
Brouard R; Laporte V; Serradeil Le Gal C; Pignol R; Jang H; Donat F; Lockwood G; Fournie D; Dreux F
Adv Exp Med Biol; 1998; 449():455-65. PubMed ID: 10026839
[TBL] [Abstract][Full Text] [Related]
20. Copeptin: Up-to-date diagnostic and prognostic role highlight.
Abdelmageed M; Güzelgül F
Anal Biochem; 2023 Jul; 673():115181. PubMed ID: 37247750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
